US › Healthcare

Compass Therapeutics Inc. (CMPX)

US · Healthcare · Biotechnology

$1.98+5.04%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-18.3M
Profit YoY
-10.1%
EPS
$-0.10
EPS estimate
$-0.10

EPS came in at -0.10 against a street estimate of -0.10 — a beat of 0.0%.

Key statistics

Market cap
$344.0M
Forward P/E
0.0
P/B
1.84
Book value
$1.03
EPS (TTM)
$-0.40
52-week high
$6.88
52-week low
$1.61
50-day MA
$2.11
200-day MA
$4.22
Beta
0.75

Analyst view

Analysts rate Compass Therapeutics Inc. a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $8.50.

Shareholding

Insiders
12.46%
Institutions
94.10%

Largest institutional holders

FundStake
TANG CAPITAL MANAGEMENT LLC9.32%
Orbimed Advisors, LLC8.45%
Suvretta Capital Management, LLC7.94%
Vivo Capital, LLC5.30%
BlackRock Inc5.28%
Adage Capital Partners Gp LLC4.71%
Enavate Sciences GP, LLC4.32%
Bvf Inc4.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Compass Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.